AxoGen and Stryker forge alliance to market nerve graft
This article was originally published in Clinica
Executive Summary
Peripheral nerve regeneration specialist AxoGen is set to bring its Avance nerve graft to a wider range of patients after signing an exclusive distribution and co-marketing agreement with Stryker Orthopaedics. The agreement sees Stryker take responsibility for distribution of the Avance graft for nerve repairs in the upper and lower extremities, and brachial plexus, while AxoGen will market the product for head, neck and torso indications. Stryker has existing sales routes in the soft tissue market for its TissueMend collagen matrix. According to Alachua, Florida-based AxoGen, the Avance graft is the only commercially available product that provides surgeons with the option to repair damaged peripheral nerves with a human allograft nerve. AxoGen describes the product as a nerve-to-nerve repair option, as it eliminates the need for second donor site surgery. Financial details of the deal were not disclosed.